In a patient with severe pulmonary hypertension who is already taking amlodipine and losartan, what medication should be added?

Severe Pulmonary Hypertension: Add PAH-Specific Therapy Immediately

Amlodipine and losartan are systemic hypertension medications that have no role in treating pulmonary arterial hypertension—you must add evidence-based PAH-specific therapy targeting the endothelin, nitric oxide, or prostacyclin pathways. 1, 2

Critical First Step: Confirm PAH Diagnosis and Risk Stratification

Before adding therapy, you need:

• Right heart catheterization with vasoreactivity testing to confirm Group 1 PAH (not pulmonary hypertension from left heart disease or other causes) and determine if the patient is a vasoreactive responder 1
• WHO functional class assessment (II, III, or IV) to guide treatment intensity 1, 2
• Risk stratification using 6-minute walk distance, NT-proBNP levels, echocardiographic findings, and hemodynamic parameters 1

Treatment Algorithm Based on Severity

For WHO Functional Class III (Severe Symptoms)

Initial combination therapy is now the standard approach:

• Add ambrisentan 10 mg daily PLUS tadalafil 40 mg daily as your first-line combination therapy 3, 2
  • This combination significantly delays clinical failure and improves 6-minute walk distance by 49 meters vs 24 meters with monotherapy (p<0.001) 3, 2
  • The AMBITION trial demonstrated this is superior to either agent alone 3

Alternative if combination therapy is not feasible:

• Add macitentan (endothelin receptor antagonist) which can be combined with phosphodiesterase-5 inhibitors 2
• Add bosentan 62.5 mg twice daily for 4 weeks, then 125 mg twice daily 1, 2
  • Requires monthly liver function monitoring due to 10-11% risk of transaminase elevation >3x upper limit of normal 1, 2

For WHO Functional Class IV (Most Severe)

Parenteral prostacyclin therapy is mandatory:

• Initiate continuous intravenous epoprostenol as first-line therapy 3, 1, 2
• This is strongly recommended for high-risk patients or those with rapidly progressive disease 1, 2
• Alternative: IV or subcutaneous treprostinil if epoprostenol is not feasible 3, 1

Why Amlodipine and Losartan Are Inappropriate

These medications target systemic hypertension, not pulmonary arterial hypertension:

• Amlodipine is a calcium channel blocker used for systemic hypertension 3
• Losartan is an angiotensin receptor blocker for systemic hypertension 3
• Calcium channel blockers are ONLY indicated in PAH for the small subset (<10%) of patients who demonstrate acute vasoreactivity during right heart catheterization 1
• Animal studies show amlodipine may have anti-remodeling properties in hypoxic pulmonary hypertension, but this has never translated to human PAH treatment 4

Critical Drug Interactions to Monitor

When adding PAH-specific therapy to existing medications:

• Bosentan + warfarin: Intensified INR monitoring required (bosentan induces warfarin metabolism) 3
• Bosentan + simvastatin/atorvastatin: Statin levels reduced by 50%; monitor cholesterol 3
• Sildenafil/tadalafil + nitrates: ABSOLUTE CONTRAINDICATION due to profound, potentially fatal hypotension 3, 2
• Bosentan + hormonal contraceptives: Contraception becomes unreliable; use barrier methods 3

Essential Supportive Therapies to Add Concurrently

• Diuretics for right ventricular failure with fluid retention 1, 2
• Supplemental oxygen if arterial oxygen pressure <60 mmHg (maintain >60 mmHg for >15 hours/day) 1
• Consider anticoagulation (target INR 1.5-2.5 in North America, 2.0-3.0 in Europe) for idiopathic PAH 1, 2
• Influenza and pneumococcal vaccination 1, 2

Monitoring for Treatment Response

Reassess at 3-6 months for:

• WHO functional class improvement 1
• 6-minute walk distance increase (>33 meters is clinically meaningful) 3
• NT-proBNP reduction 5
• Echocardiographic improvement in right ventricular function 5

If inadequate response: Add a third agent from a different drug class or consider referral for lung transplantation evaluation 1, 2

Common Pitfalls

• Do not continue amlodipine/losartan as "PAH therapy"—they provide no benefit for pulmonary vascular disease 1
• Do not delay referral to a specialized pulmonary hypertension center—this worsens outcomes 1
• Do not use monotherapy in WHO FC III-IV patients—combination therapy is now standard 3, 2
• Do not forget liver function monitoring with endothelin receptor antagonists—check monthly 1, 2
• Pregnancy is absolutely contraindicated (30-50% mortality risk) 1